Investing.com - Theravance Biopharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Theravance Biopharma announced earnings per share of $12.14 on revenue of $12.45M. Analysts polled by Investing.com anticipated EPS of $-0.05 on revenue of $11.45M.
Theravance Biopharma shares are up 19.33% from the beginning of the year , still down 23.69% from its 52 week high of $13.17 set on Monday, January 10, 2022.
Theravance Biopharma follows other major Healthcare sector earnings this month
Theravance Biopharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar